Proteomic diversity of high density lipoproteins: Our emerging understanding of its importance in lipid transport and beyond

Journal of Lipid Research

Volumn 54, Issue 10, 2013, Pages 2575-2585

  Shah, Amy S ^a   Tan, Lirong ^b   Long, Jason Lu ^b   Davidson, W Sean ^c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Apolipoproteins; Complement; Function; Hemostasis; Inflammation; Innate immunity; Lipid metabolism; Mass spectrometry; Protease inhibition

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN;

FUNCTIONAL PROTEOMICS; HUMAN; LIPID TRANSPORT; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW;

APOLIPOPROTEINS; COMPLEMENT; FUNCTION; HEMOSTASIS; INFLAMMATION; INNATE IMMUNITY; LIPID METABOLISM; MASS SPECTROMETRY; PROTEASE INHIBITION;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; LIPID METABOLISM; LIPOPROTEINS, HDL; MASS SPECTROMETRY; PROTEOME; PROTEOMICS;

EID: 84884138140     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R035725     Document Type: Review

References (110)

1. Macheboeuf, M. 1929. Recherches sur les phosphoaminolipides du sérum sanguin. Nature des phospholipides liés aux albumines du sérum de Cheval à l'état de cenapses acido- précipitables. Bull. Soc. Chim. Biol. (Paris). 11: 485-503.
2. Shore, B., and V. Shore. 1968. Heterogeneity in protein subunits of human serum high-density lipoproteins. Biochemistry. 7: 2773-2777.
3. Scanu, A., J. Toth, C. Edelstein, S. Koga, and E. Stiller. 1969. Fractionation of human serum high density lipoprotein in urea solutions. Evidence for polypeptide heterogeneity. Biochemistry. 8: 3309-3316.
4. Rudman, D., L. A. Garcia, and C. H. Howard. 1970. A new method for isolating the nonidentical protein subunits of human plasma alpha-lipoprotein. J. Clin. Invest. 49: 365-372.
5. Kostner, G., and P. Alaupovic. 1971. Studies of the composition and structure of plasma lipoproteins. C- and N-terminal amino acids of the two nonidentical polypeptides of human plasma apolipoprotein A. FEBS Lett. 15: 320-324.
6. Shore, B., and V. Shore. 1969. Isolation and characterization of polypeptides of human serum lipoproteins. Biochemistry. 8: 4510-4516.
7. Mahley, R. W., and T. L. Innerarity. 1977. Interaction of canine and swine lipoproteins with the low density lipoprotein receptor of fibroblasts as correlated with heparin/manganese precipitability. J. Biol. Chem. 252: 3980-3986.
8. Ayrault-Jarrier, M., J. F. Alix, and J. Polonovski. 1980. Presence and isolation of 2 lipoproteins immunologically related to apolipoprotein A I in human serum [article in French]. Biochimie. 62: 51-59.
9. Olofsson, S. O., W. J. McConathy, and P. Alaupovic. 1978. Isolation and partial characterization of a new acidic apolipoprotein (apolipoprotein F) from high density lipoproteins of human plasma. Biochemistry. 17: 1032-1036.
10. Bausserman, L. L., P. N. Herbert, and K. P. McAdam. 1980. Heterogeneity of human serum amyloid A proteins. J. Exp. Med. 152: 641-656.
11. Vézina, C. A., R. W. Milne, P. K. Weech, and Y. L. Marcel. 1988. Apolipoprotein distribution in human lipoproteins separated by polyacrylamide gradient gel electrophoresis. J. Lipid Res. 29: 573-585.
12. Blatter, M. C., R. W. James, S. Messmer, F. Barja, and D. Pometta. 1993. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur. J. Biochem. 211: 871-879.
13. Campos, E., and W. J. McConathy. 1986. Distribution of lipids and apolipoproteins in human plasma by vertical spin ultracentrifugation. Arch. Biochem. Biophys. 249: 455-463.
14. Marcel, Y. L., C. Vezina, B. Teng, and A. Sniderman. 1980. Transfer of cholesterol esters between human high density lipoproteins and triglyceride-rich lipoproteins controlled by a plasma protein factor. Atherosclerosis. 35: 127-133.
15. Tall, A. R., S. Krumholz, T. Olivecrona, and R. J. Deckelbaum. 1985. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J. Lipid Res. 26: 842-851.
16. Stafforini, D. M., T. M. McIntyre, M. E. Carter, and S. M. Prescott. 1987. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J. Biol. Chem. 262: 4215-4222.
17. James, R. W., D. Hochstrasser, J. D. Tissot, M. Funk, R. Appel, F. Barja, C. Pellegrini, A. F. Muller, and D. Pometta. 1988. Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human plasma. J. Lipid Res. 29: 1557-1571.
18. Fenn, J. B., M. Mann, C. K. Meng, S. F. Wong, and C. M. Whitehouse. 1989. Electrospray ionization for mass spectrometry of large biomolecules. Science. 246: 64-71.
19. Hillenkamp, F., M. Karas, R. C. Beavis, and B. T. Chait. 1991. Matrix-assisted laser desorption/ionization mass spectrometry of biopolymers. Anal. Chem. 63: 1193A - 1203A.
20. Cañas, B., D. López-Ferrer, A. Ramos-Fernández, E. Camafeita, and E. Calvo. 2006. Mass spectrometry technologies for proteomics. Brief Funct. Genomic Proteomic. 4: 295-320.
21. Karlsson, H., Leanderson, C. Tagesson, and M. Lindahl. 2005. Lipoproteomics II: Mapping of Proteins in High-density Lipoprotein Using Two-dimensional Gel Electrophoresis and Mass Spectrometry. Proteomics. 5: 1431-1445.
22. Rezaee, F., B. Casetta, J. H. Levels, D. Speijer, and J. C. Meijers. 2006. Proteomic analysis of high-density lipoprotein. Proteomics. 6: 721-730.
23. Vaisar, T., S. Pennathur, P. S. Green, S. A. Gharib, A. N. Hoofnagle, M. C. Cheung, J. Byun, S. Vuletic, S. Kassim, P. Singh, et al. 2007. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117: 746-756.
24. Heller, M., D. Stalder, E. Schlappritzi, G. Hayn, U. Matter, and A. Haeberli. 2005. Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins. Proteomics. 5: 2619-2630.
25. Hortin, G. L., R. F. Shen, B. M. Martin, and A. T. Remaley. 2006. Diverse range of small peptides associated with high-density lipoprotein. Biochem. Biophys. Res. Commun. 340: 909-915.
26. Davidson, W. S., R. A. Silva, S. Chantepie, W. R. Lagor, M. J. Chapman, and A. Kontush. 2009. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 29: 870-876.
27. Alwaili, K., D. Bailey, Z. Awan, S. D. Bailey, I. Ruel, A. Hafiane, L. Krimbou, S. Laboissiere, and J. Genest. 2012. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim. Biophys. Acta. 1821: 405-415.
28. Holzer, M., P. Wolf, S. Curcic, R. Birner-Gruenberger, W. Weger, M. Inzinger, D. El-Gamal, C. Wadsack, A. Heinemann, and G. Marsche. 2012. Psoriasis alters HDL composition and cholesterol efflux capacity. J. Lipid Res. 53: 1618-1624.
29. Holzer, M., R. Birner-Gruenberger, T. Stojakovic, D. El-Gamal, V. Binder, C. Wadsack, A. Heinemann, and G. Marsche. 2011. Uremia alters HDL composition and function. J. Am. Soc. Nephrol. 22: 1631-1641.
30. Weichhart, T., C. Kopecky, M. Kubicek, M. Haidinger, D. Doller, K. Katholnig, C. Suarna, P. Eller, M. Tolle, C. Gerner, et al. 2012. Serum amyloid A in uremic HDL promotes inflammation. J. Am. Soc. Nephrol. 23: 934-947.
31. Mangé, A., A. Goux, S. Badiou, L. Patrier, B. Canaud, T. Maudelonde, J. P. Cristol, and J. Solassol. 2012. HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography- tandem mass spectrometry approach. PLoS ONE. 7: e34107.
32. Watanabe, J., C. Charles-Schoeman, Y. Miao, D. Elashoff, Y. Y. Lee, G. Katselis, T. D. Lee, and S. T. Reddy. 2012. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum. 64: 1828-1837.
33. Gordon, S. M., J. Deng, L. J. Lu, and W. S. Davidson. 2010. Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J. Proteome Res. 9: 5239-5249.
34. Adorni, M. P., F. Zimetti, J. T. Billheimer, N. Wang, D. J. Rader, M. C. Phillips, and G. H. Rothblat. 2007. The roles of different pathways in the release of cholesterol from macrophages. J. Lipid Res. 48: 2453-2462.
35. Gu, X., B. Trigatti, S. Xu, S. Acton, J. Babitt, and M. Krieger. 1998. The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptormediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain. J. Biol. Chem. 273: 26338-26348.
36. [Erratum. 1998. J. Biol. Chem. 273: 35388.]
37. Moore, R. E., M. Navab, J. S. Millar, F. Zimetti, S. Hama, G. H. Rothblat, and D. J. Rader. 2005. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ. Res. 97: 763-771.
38. Navab, M., S. Y. Hama, G. M. Anantharamaiah, K. Hassan, G. P. Hough, A. D. Watson, S. T. Reddy, A. Sevanian, G. C. Fonarow, and A. M. Fogelman. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein. Steps 2 and 3. J. Lipid Res. 41: 1495-1508.
39. Rye, K. A., C. A. Bursill, G. Lambert, F. Tabet, and P. J. Barter. 2009. The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50 (Suppl.) : S195 - S200.
40. Barter, P. J., and K. A. Rye. 1996. High density lipoproteins and coronary heart disease. Atherosclerosis. 121: 1-12.
41. Navab, M., S. S. Imes, S. Y. Hama, G. P. Hough, L. A. Ross, R. W. Bork, A. J. Valente, J. A. Berliner, D. C. Drinkwater, and H. Laks. 1991. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88: 2039-2046.
42. Puranik, R., S. Bao, E. Nobecourt, S. J. Nicholls, G. J. Dusting, P. J. Barter, D. S. Celermajer, and K. A. Rye. 2008. Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis. 196: 240-247.
43. Kontush, A., and M. J. Chapman. 2012. High-Density Lipoproteins: Structure, Metabolism, Function and Therapeutics. John Wiley & Sons, Hoboken, NJ.
44. Ingenbleek, Y., and V. Young. 1994. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu. Rev. Nutr. 14: 495-533.
45. McAdam, K. P., and J. D. Sipe. 1976. Murine model for human secondary amyloidosis: genetic variability of the acute-phase serum protein SAA response to endotoxins and casein. J. Exp. Med. 144: 1121-1127.
46. Artl, A., G. Marsche, S. Lestavel, W. Sattler, and E. Malle. 2000. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler. Thromb. Vasc. Biol. 20: 763-772.
47. Annema, W., N. Nijstad, M. Tolle, J. F. de Boer, R. V. Buijs, P. Heeringa, M. van der Giet, and U. J. Tietge. 2010. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). J. Lipid Res. 51: 743-754.
48. Cai, L., A. Ji, F. C. de Beer, L. R. Tannock, and D. R. van der Westhuyzen. 2008. SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J. Clin. Invest. 118: 364-375.
49. Ancsin, J. B., and R. Kisilevsky. 1999. The heparin/heparan sulfatebinding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J. Biol. Chem. 274: 7172-7181.
50. Chait, A., C. Y. Han, J. F. Oram, and J. W. Heinecke. 2005. Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J. Lipid Res. 46: 389-403.
51. Rosenfeld, S. I., C. H. Packman, and J. P. Leddy. 1983. Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins. J. Clin. Invest. 71: 795-808.
52. Hailman, E., H. S. Lichenstein, M. M. Wurfel, D. S. Miller, D. A. Johnson, M. Kelley, L. A. Busse, M. M. Zukowski, and S. D. Wright. 1994. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J. Exp. Med. 179: 269-277.
53. Jahangiri, A. 2010. High-density lipoprotein and the acute phase response. Curr. Opin. Endocrinol. Diabetes Obes. 17: 156-160.
54. Nofer, J. R., M. F. Brodde, and B. E. Kehrel. 2010. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin. Exp. Pharmacol. Physiol. 37: 726-735.
55. Wang, P., Y. Wang, W. Ma, H. Li, and H. Chen. 2013. High-density lipoprotein cholesterol and intracoronary thrombosis burden. Coron. Artery Dis. 24: 1-5.
56. Wang, Y., P. Wang, and H. Li. 2010. Correlation study of pulmonary embolism and high-density lipoprotein cholesterol. Clin. Cardiol. 33: 72-76.
57. Aviram, M., C. R. Sirtori, S. Colli, P. Maderna, G. Morazzoni, and E. Tremoli. 1985. Plasma lipoproteins affect platelet malondialdehyde and thromboxane B2 production. Biochem. Med. 34: 29-36.
58. Mehta, J. L., and L. Y. Chen. 1996. Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets. J. Lab. Clin. Med. 127: 287-295.
59. Griffin, J. H., K. Kojima, C. L. Banka, L. K. Curtiss, and J. A. Fernandez. 1999. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J. Clin. Invest. 103: 219-227.
60. Oslakovic, C., E. Norstrom, and B. Dahlback. 2010. Reevaluation of the role of HDL in the anticoagulant activated protein C system in humans. J. Clin. Invest. 120: 1396-1399.
61. Dole, V. S., J. Matuskova, E. Vasile, A. Yesilaltay, W. Bergmeier, M. Bernimoulin, D. D. Wagner, and M. Krieger. 2008. Thrombocytopenia and platelet abnormalities in high-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 28: 1111-1116.
62. Calkin, A. C., B. G. Drew, A. Ono, S. J. Duffy, M. V. Gordon, S. M. Schoenwaelder, D. Sviridov, M. E. Cooper, B. A. Kingwell, and S. P. Jackson. 2009. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation. 120: 2095-2104.
63. Concha, M. I., V. J. Smith, K. Castro, A. Bastias, A. Romero, and R. J. Amthauer. 2004. Apolipoproteins A-I and A-II are potentially important effectors of innate immunity in the teleost fish Cyprinus carpio. Eur. J. Biochem. 271: 2984-2990.
64. Villarroel, F., A. Bastias, A. Casado, R. Amthauer, and M. I. Concha. 2007. Apolipoprotein A-I, an antimicrobial protein in Oncorhynchus mykiss: evaluation of its expression in primary defence barriers and plasma levels in sick and healthy fish. Fish Shellfish Immunol. 23: 197-209.
65. Johnston, L. D., G. Brown, D. Gauthier, K. Reece, H. Kator, and V. P. Van. 2008. Apolipoprotein A-I from striped bass (Morone saxatilis) demonstrates antibacterial activity in vitro. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 151: 167-175.
66. Cruz, D., A. D. Watson, C. S. Miller, D. Montoya, M. T. Ochoa, P. A. Sieling, M. A. Gutierrez, M. Navab, S. T. Reddy, J. L. Witztum, et al. 2008. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J. Clin. Invest. 118: 2917-2928.
67. Figueirêdo, P. M., C. F. Catani, and T. Yano. 2003. Serum highdensity lipoprotein (HDL) inhibits in vitro enterohemolysin (EHly) activity produced by enteropathogenic Escherichia coli. FEMS Immunol. Med. Microbiol. 38: 53-57.
68. Grunfeld, C., M. Marshall, J. K. Shigenaga, A. H. Moser, P. Tobias, and K. R. Feingold. 1999. Lipoproteins inhibit macrophage activation by lipoteichoic acid. J. Lipid Res. 40: 245-252.
69. Ma, J., X. L. Liao, B. Lou, and M. P. Wu. 2004. Role of apolipoprotein A-I in protecting against endotoxin toxicity. Acta Biochim. Biophys. Sin. (Shanghai). 36: 419-424.
70. Parker, T. S., D. M. Levine, J. C. Chang, J. Laxer, C. C. Coffin, and A. L. Rubin. 1995. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect. Immun. 63: 253-258.
71. Jiao, Y. L., and M. P. Wu. 2008. Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine. 43: 83-87.
72. Li, Y., J. B. Dong, and M. P. Wu. 2008. Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice. Eur. J. Pharmacol. 590: 417-422.
73. Feingold, K. R., and C. Grunfeld. 2011. The role of HDL in innate immunity. J. Lipid Res. 52: 1-3.
74. Courtney, H. S., Y. M. Zhang, M. W. Frank, and C. O. Rock. 2006. Serum opacity factor, a streptococcal virulence factor that binds to apolipoproteins A-I and A-II and disrupts high density lipoprotein structure. J. Biol. Chem. 281: 5515-5521.
75. Vaisar, T., P. Mayer, E. Nilsson, X. Q. Zhao, R. Knopp, and B. J. Prazen. 2010. HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin. Chim. Acta. 411: 972-979.
76. Green, P. S., T. Vaisar, S. Pennathur, J. J. Kulstad, A. B. Moore, S. Marcovina, J. Brunzell, R. H. Knopp, X. Q. Zhao, and J. W. Heinecke. 2008. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation. 118: 1259-1267.
77. Krauss, R. M., K. Wojnooski, J. Orr, J. C. Geaney, C. A. Pinto, Y. Liu, J. A. Wagner, J. M. Luk, A. O. Johnson-Levonas, M. S. Anderson, et al. 2012. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J. Lipid Res. 53: 540-547.
78. Hoofnagle, A. N., M. Wu, A. K. Gosmanova, J. O. Becker, E. M. Wijsman, J. D. Brunzell, S. E. Kahn, R. H. Knopp, T. J. Lyons, and J. W. Heinecke. 2010. Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia. Arterioscler. Thromb. Vasc. Biol. 30: 2528-2534.
79. Rubinow, K. B., C. Tang, A. N. Hoofnagle, C. N. Snyder, J. K. Amory, J. W. Heinecke, and S. T. Page. 2012. Acute sex steroid withdrawal increases cholesterol efflux capacity and HDLassociated clusterin in men. Steroids. 77: 454-460.
80. Rubinow, K. B., T. Vaisar, C. Tang, A. M. Matsumoto, J. W. Heinecke, and S. T. Page. 2012. Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity. J. Lipid Res. 53: 1376-1383.
81. Boyle, K. E., M. C. Phillips, and S. Lund-Katz. 1999. Kinetics and mechanism of exchange of apolipoprotein C-III molecules from very low density lipoprotein particles. Biochim. Biophys. Acta. 1430: 302-312.
82. Asztalos, B. F., and E. J. Schaefer. 2003. High-density lipoprotein subpopulations in pathologic conditions. Am. J. Cardiol. 91: 12E - 17E.
83. Santos, R. D., E. J. Schaefer, B. F. Asztalos, E. Polisecki, J. Wang, R. A. Hegele, L. R. Martinez, M. H. Miname, C. E. Rochitte, P. L. Da Luz, et al. 2008. Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency. J. Lipid Res. 49: 349-357.
84. Gordon, S. M., J. Deng, A. B. Tomann, A. S. Shah, L. J. Lu, and W. S. Davidson. 2013. Multi-dimensional co-separation analysis reveals protein:protein interactions defining plasma lipoprotein subspecies. Mol Cell Proteomics. Epub ahead of print. July 23, 2013; doi: 10.1074/mcp.M113.028134.
85. Jonas, A. 1991. Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. Biochim. Biophys. Acta. 1084: 205-220.
86. Kinnunen, P. K., R. L. Jackson, L. C. Smith, A. M. Gotto, Jr ., and J. T. Sparrow. 1977. Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II. Proc. Natl. Acad. Sci. USA. 74: 4848-4851.
87. Jahangiri, A., D. J. Rader, D. Marchadier, L. K. Curtiss, D. J. Bonnet, and K. A. Rye. 2005. Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. J. Lipid Res. 46: 896-903.
88. Wang, X., D. M. Driscoll, and R. E. Morton. 1999. Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F. J. Biol. Chem. 274: 1814-1820.
89. Mackness, M. I., S. Arrol, and P. N. Durrington. 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286: 152-154.
90. Aviram, M., S. Billecke, R. Sorenson, C. Bisgaier, R. Newton, M. Rosenblat, J. Erogul, C. Hsu, C. Dunlop, and B. La Du. 1998. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18: 1617-1624.
91. Watson, A. D., J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab. 1995. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96: 2882-2891.
92. Mackness, M. I., and P. N. Durrington. 1995. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 115: 243-253.
93. Loued, S., M. Isabelle, H. Berrougui, and A. Khalil. 2012. The anti-inflammatory effect of paraoxonase 1 against oxidized lipids depends on its association with high density lipoproteins. Life Sci. 90: 82-88.
94. Aviram, M., M. Rosenblat, C. L. Bisgaier, R. S. Newton, S. L. Primo- Parmo, and B. N. La Du. 1998. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101: 1581-1590.
95. Hine, D., B. Mackness, and M. Mackness. 2012. Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation. IUBMB Life. 64: 157-161.
96. Rifkin, M. R. 1978. Identification of the trypanocidal factor in normal human serum: high density lipoprotein. Proc. Natl. Acad. Sci. USA. 75: 3450-3454.
97. Hajduk, S. L., D. R. Moore, J. Vasudevacharya, H. Siqueira, A. F. Torri, E. M. Tytler, and J. D. Esko. 1989. Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein. J. Biol. Chem. 264: 5210-5217.
98. Vanhamme, L., F. Paturiaux-Hanocq, P. Poelvoorde, D. P. Nolan, L. Lins, J. Van den Abbeele, A. Pays, P. Tebabi, X. H. Van, A. Jacquet, et al. 2003. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature. 422: 83-87.
99. Vanhollebeke, B., M. J. Nielsen, Y. Watanabe, P. Truc, L. Vanhamme, K. Nakajima, S. K. Moestrup, and E. Pays. 2007. Distinct roles of haptoglobin-related protein and apolipoprotein L-I in trypanolysis by human serum. Proc. Natl. Acad. Sci. USA. 104: 4118-4123.
100. Shiflett, A. M., J. R. Bishop, A. Pahwa, and S. L. Hajduk. 2005. Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J. Biol. Chem. 280: 32578-32585.
101. Cheung, M. C., T. Vaisar, X. Han, J. W. Heinecke, and J. J. Albers. 2010. Phospholipid transfer protein in human plasma associates with proteins linked to immunity and inflammation. Biochemistry. 49: 7314-7322.
102. Hoofnagle, A. N., J. O. Becker, M. N. Oda, G. Cavigiolio, P. Mayer, and T. Vaisar. 2012. Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. Clin. Chem. 58: 777-781.
103. Jensen, M. K., E. B. Rimm, J. D. Furtado, and F. M. Sacks. 2012. Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease. J. Am. Heart Assoc. 1: jah3-e000232.
104. Boden, W. E., J. L. Probstfield, T. Anderson, B. R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, and W. Weintraub. 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365: 2255-2267.
105. Barter, P. J., M. Caulfield, M. Eriksson, S. M. Grundy, J. J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. C. Tardif, D. D. Waters, et al. 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357: 2109-2122.
106. Schwartz, G. G., A. G. Olsson, M. Abt, C. M. Ballantyne, P. J. Barter, J. Brumm, B. R. Chaitman, I. M. Holme, D. Kallend, L. A. Leiter, et al. 2012. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367: 2089-2099.
107. Larach, D. B., E. M. Degoma, and D. J. Rader. 2012. Targeting high density lipoproteins in the prevention of cardiovascular disease? Curr. Cardiol. Rep. 14: 684-691.
108. Khera, A. V., M. Cuchel, M. Llera-Moya, A. Rodrigues, M. F. Burke, K. Jafri, B. C. French, J. A. Phillips, M. L. Mucksavage, R. L. Wilensky, et al. 2011. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364: 127-135.
109. Ansell, B. J., M. Navab, S. Hama, N. Kamranpour, G. Fonarow, G. Hough, S. Rahmani, R. Mottahedeh, R. Dave, S. T. Reddy, et al. 2003. Inflammatory/ antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 108: 2751-2756.
110. Vergeer, M., M. L. Bots, S. I. van Leuven, D. C. Basart, E. J. Sijbrands, G. W. Evans, D. E. Grobbee, F. L. Visseren, A. F. Stalenhoef, E. S. Stroes, et al. 2008. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 118: 2515-2522.